<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441528</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2021</org_study_id>
    <nct_id>NCT04441528</nct_id>
  </id_info>
  <brief_title>Lid Wipes Versus Baby Shampoo in Patients With Seborrehic Blepharitis</brief_title>
  <official_title>Randomized Double-Blind Trial of Lid Wipes Containing Terpinen-4-ol and Sodium Hyaluronate Versus Baby Shampoo in Patients With Seborrheic Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Koç University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istanbul University-Cerrahpasa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of lid wipes containing
      terpinen-4-ol and sodium hyaluronate (Hy-ter®) for the treatment of seborrheic blepharitis
      compared to baby shampoo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written consent
      will have a complete ophthalmological examination to determine eligibilty for study entry. At
      week 0, patients who meet the eligibility requirements will be randomized in a double blind
      manner (participant and investigator) in a 1:1 ratio to lid wipes containing terpinen-4-ol
      and sodium hyaluronate (Hy-ter®) or baby shampoo (twice daily).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the treatment assessed by the change in Blepharitis Symptom measure (BLISS) score</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>BLISS score is calculated according to the answers given to the questionnaire. Higher BLISS scores is related to a worse outcome. (Range is between 0 and 39)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment assessed by the change in Demodex mite count by light microscopy</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>The number of mites in the epilated 4 eyelashes will be counted under microscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment assessed by the change in the Schirmer test results</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>Dry eye evaluation will be made with Schirmer test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment assessed by the change in the tear breakup time</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>Dry eye evaluation will be made with tear breakup time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment assessed by the change in the ocular surface disease index score</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>OSDI scores are calculated according to the responses to the questionnaire. Higher values are related to a worse outcome (range is between 0-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment assessed by the change in the non-invasive tear breakup time</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>Dry eye evaluation will be made with non-invasive tear breakup time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment assessed by the change in the meibomian gland loss</measure>
    <time_frame>0-4-8-12 weeks</time_frame>
    <description>Meibomian gland loss will be evaluated using anterior segment analysis system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Seborrheic Blepharitis</condition>
  <arm_group>
    <arm_group_label>Lid wipes containing terpinen-4-ol and sodium hyaluronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The lid wipes will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baby shampoo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lid wipes containing terpinen-4-ol and sodium hyaluronate</intervention_name>
    <description>Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.</description>
    <arm_group_label>Lid wipes containing terpinen-4-ol and sodium hyaluronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baby shampoo</intervention_name>
    <description>Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.</description>
    <arm_group_label>Baby shampoo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of seborrheic blepharitis

        Exclusion Criteria:

          -  Patients with ophthalmological pathologies that may affect the tear film functions
             including ocular rosacea, contact lens use, history of any ocular surgery, or patients
             with systemic pathologies or those using systemic medications that may affect the tear
             film functions

          -  Patients younger than 18-year-old

          -  Patients who used any treatment for blepharitis within the 6 months prior to the
             examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul University-Cerrahpasa</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University-Cerrahpasa</investigator_affiliation>
    <investigator_full_name>Ceyhun Arici, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>seborrheic blepharitis</keyword>
  <keyword>terpinen-4-ol</keyword>
  <keyword>baby shampoo</keyword>
  <keyword>lid wipes</keyword>
  <keyword>sodium hyaluronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

